Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Current heart failure therapies do not address reduced cardiac contractility.
• Traditional inotropes (calcitropes) worsen survival due to increased energy demand.
• Myotropes represent a new class of agents that activate the sarcomere directly, independent of calcium.

Purpose of the Study:

• To investigate the effects of a novel myotrope, TA1, on cardiac contractility.
• To compare the myocardial energetic impact of TA1 with a traditional inotrope, dobutamine.

Main Methods:

• Experiments were conducted on cardiac myofibrils, microtissues, fibers, and in vivo models.
• ³¹P nuclear magnetic resonance spectroscopy was used to assess myocardial energetics in isolated rat hearts.

Main Results:

• TA1 increased myocardial contractility and calcium sensitivity without altering cardiac energy levels.
• Dobutamine increased contractility but also depleted cardiac energy reserves and worsened diastolic function.
• TA1 demonstrated a similar increase in cardiac workload (rate-pressure product) as dobutamine but without adverse energetic consequences.

Conclusions:

• Novel myotrope TA1 enhances myocardial contractility by sensitizing the sarcomere to calcium.
• TA1 improves cardiac function without impairing diastolic function or depleting cardiac energy reserves.
• Myotropes may offer a superior therapeutic strategy for heart failure compared to traditional inotropes due to their favorable energetic profile.